GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R …
2017年12月7日 · We added GMI-1271 to salvage with MEC for relapsed/refractory AML patients or to induction with 7+3 for older treatment naïve (TN) AML patients. Methods A Phase (Ph) 1 trial escalated GMI-1271 (5-20 mg/kg) combined with MEC (mitoxantrone, etoposide, cytarabine) in pts with R/R AML, to evaluate safety, tolerability and anti-leukemic activity.
Targeting hematologic malignancies by inhibiting E-selectin: A …
2024年5月1日 · Uproleselan (GMI-1271) is a carbohydrate analog of sialyl Lewis x that blocks E-selectin binding. A Phase 2 trial of MEC chemotherapy combined with uproleselan for relapsed/refractory AML showed a median overall survival of 8.8 months and low (2%) rates of severe oral mucositis.
A Phase I/II Study of GMI-1271, a Novel E-Selectin ... - ScienceDirect
2016年12月2日 · GMI-1271 is a novel antagonist of E-sel, putatively disrupting leukemia cell survival pathways and enhancing chemotherapy response. We performed a phase 1/2 trial of GMI-1271 plus MEC (mitoxantrone, etoposide and cytarabine) for the treatment of relapsed/refractory (R/R) and a pilot study adding GMI-1271 to …
GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R …
2017年12月8日 · A Phase (Ph) 1 trial escalated GMI-1271 (5-20 mg/kg) combined with MEC (mitoxantrone, etoposide, cytarabine) in pts with R/R AML, to evaluate safety, tolerability and anti-leukemic activity. Dose limiting toxicity (DLT) was defined as persistent cytopenias in the absence of disease or any Grade 3-5 non-hematologic toxicity beyond day 42.
Once the recommended phase 2 dose (RP2D) was selected, Phase 2 dose expansion continued enrolling patients with R/R AML (Phase 2, Arm A) and added the option for responders to proceed to 1 cycle of consolidation with GMI-1271 and reduced course of MEC.
Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the …
2018年11月29日 · Uproleselan (GMI-1271), a novel E-sel antagonist, disrupts cell survival pathway activation, enhances chemotherapy response and protects from toxicity with improved survival in vivo.
A Phase I/II Study of GMI-1271, a Novel E-Selectin Antagonist, in ...
2016年12月2日 · GMI-1271 is a novel antagonist of E-sel, putatively disrupting leukemia cell survival pathways and enhancing chemotherapy response. We performed a phase 1/2 trial of GMI-1271 plus MEC (mitoxantrone, etoposide and cytarabine) for the treatment of relapsed/refractory (R/R) and a pilot study adding GMI-1271 to …
Phase 3 Study of Uproleselan for R/R AML to Continue to Final OS …
2023年2月15日 · A pivotal phase 3 study (NCT03616470) of uproleselan (GMI-1271) in relapsed/refractory (R/R) acute myeloid leukemia (AML) has been reviewed by the Data Monitoring Committee (DMC) and was recommended to continue to the originally planned final overall survival (OS) events trigger, according to GlycoMimetics, Inc. 1 The interim utility analysis was added to the study and conducted in fall 2022 ...
A phase III trial to evaluate the efficacy of uproleselan (GMI-1271 ...
2019年5月26日 · A phase III trial to evaluate the efficacy of uproleselan (GMI-1271) with chemotherapy in patients with relapsed/refractory acute myeloid leukemia.
GMI-1271, a novel E-selectin antagonist, in combination with ...
2017年5月30日 · Background: GMI-1271 is a novel antagonist of E-selectin (E-sel) that down-regulates cell survival pathways and enhances chemotherapy response. We assessed GMI-1271 plus salvage chemotherapy with mitoxantrone, etoposide, and cytarabine (MEC) for the treatment of patients (pts) with relapsed/refractory (R/R) AML.